Kidney cancer patients respond well to a combination of 2 existing anti-cancer drugs

(ECCO-the European CanCer Organisation) Researchers have found that patients with an advanced form of kidney cancer, for which there is no standard treatment and a very poor prognosis, respond well to a combination of two existing anti-cancer drugs. The 26th EORTC-NCI-AACR Symposium will hear that the combination of bevacizumab and erlotinib produced excellent response rates in patients with advanced papillary renal cell carcinoma (pRCC) and in patients with a highly aggressive form of pRCC called hereditary leiomyomatosis and renal cell cancer.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news